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Abstract
According to World Health Organization (WHO) current updates, the COVID-19 pandemic has 
spread all over the globe affecting 216 countries and caused 8,860,331 confirmed cases and 
465,740 deaths last followed by 24 June 2020. Many countries cannot afford the nucleic acid 
tests to confirm COVID-19 infected patients; as a result, people cannot know the COVID-19 
status of the people living around them. The use of dexamethasone in COVID-19 hospitalized 
patients for up to 10 days lower 28-day mortality as compared to the patients taking usual care 
and also receiving mechanical ventilation at randomization (by age-adjusted percentage points 
12.3, approximately one third of proportional reduction) and those patients receiving oxygen 
without invasive mechanical ventilation (by age-adjusted percentage points 4.1, approximately 
one fifth of proportional reduction).
Introduction
According to World Health Organization (WHO) current updates,  the COVID-19 pan-
demic has spread all over the globe affecting 216 countries and caused 8,860,331 con-
firmed cases and 465,740 deaths last followed by 24 June 2020. [1] Many countries 
cannot afford the nucleic acid tests to confirm COVID-19 infected patients; as a result, 
people cannot know the COVID-19 status of the people living around them.
Since the last century with the advent of technology and advancement, it was barely rare 
to see such pandemic. It has been a new, unique, and challenging condition for the whole 
world including Science. America being the technology king and one of the developed 
countries had worst affected by this virus. Currently, the registered confirmed cases in 
America are 2,241,178 with 119,453 deaths. Brazil has been affected as the second most 
country with registered cases of 1,067,579 with 49,976 deaths. Russian Federation is the 
third country with registered cases 592,280 with 8,206 deaths. [1] The overall global 
count for the cases is 8,860,331 with 465,740 deaths (Figure 1). Interestingly all these 
conditions are developed and highly technologically advanced countries. Pakistan is also 
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Figure 1. Current status of COVID-19 across the globe.
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affected very badly by the current virus. The first case was reported on 26 February 2020 and it is increasing exponen-
tially and now the active number of cases are 181,088 and 3,590 deaths were reported to WHO on June 22, 2020. [1] The 
government has taken substantial measurements and Quarantine has been established in major emergency centers, but 
still, the cases of COVID-19 have increased very rapidly.
Methods
The COVID-19 infection spread from person to person; therefore, the affected COVID-19 patients are kept in isolation 
where they are given treatments. Currently, no specific antiviral drugs or vaccines are available for treating COVID-19. 
The COVID-19 patients are given empiric therapy which includes HIV protease inhibitors and also broad-spectrum an-
tiviral drugs like nucleoside analog that could attenuate the infection until the availability of specific antiviral drugs. [2]
The WHO also recommends convalescent plasma for the treatment of COVID-19 patients. But recently, the promising 
results of the clinical trials of dexamethasone in the United Kingdom were welcomed by WHO. The dexamethasone, 
a corticosteroid, can be life-saving for seriously ill COVID-19 patients. [3] The preliminary reports shared with the 
WHO showed that dexamethasone reduced mortality by one third in patients on ventilators, and by one fifth in pa-
tients requiring only oxygen. The effectiveness of this drug was only observed in critically ill COVID-19 patients and 
was not reported in patients with milder symptoms of the disease. The WHO Director-General, Dr. Tedros Adhanom 
Ghebreyesus has said that it is the first drug to have reduced mortality in patients in COVID-19 patients on ventilators 
or requiring oxygen. [3] 
Results
Dexamethasone, steroid, that reduces inflammation (the main cause of death in COVID-19 patients, lungs swells during 
the fight with the virus) has been used in different conditions like certain cancers and inflammatory disorders since 
the 1960s. It has been included in the WHO Model List of Essential Medicines, in many formulations since 1977, and is 
currently affordable and off-patent in most of the countries. [3]
Advantages of Dexamethasone
It has been shown that dexamethasone saves lives: a clinical trial over 4 weeks in the Oxford University observed that 
it reduced the mortality rate by 35% in COVID-19 patients on ventilators and 20% in those who needed oxygen only. 
Studies have shown that this drug would prevent the death of 1 patient for every 8 COVID-19 patients on ventilators and 
1 for every 25 COVID-19 patients who need supplemental oxygen only. Another key advantage of this drug is that it is 
cheap and easily available in most of the countries worldwide.
Side effects of Dexamethasone
Dexamethasone is an only useful drug for treating critically ill COVID-19 patients, but there are some side effects of 
using steroids, including water retention, weight gain, high blood pressure, sleep problems, mood changes, and raise 
the blood sugar level in diabetic patients. However, some researchers have also reported that the mortality rate was 
high during a clinical trial: the mortality rate in COVID-19 patients on ventilators and oxygen alone were 41% and 
25% respectively. This mortality rate seems higher than in the United States, where recently mortality rate of 12% was 
found, although it was only 2 weeks versus 4 in the United Kingdom study, said Dr. Peter Bach a health policy expert at 
Memorial Sloan-Kettering Cancer Centre in New York.
Discussion
The preliminary results of a study conducted by Group (Table 1) showed that the use of dexamethasone in COVID-19 
hospitalized patients for up to 10 days lower 28-day mortality as compared to the patients taking usual care and also 
receiving mechanical ventilation at randomization (by age-adjusted percentage points 12.3, approximately one third of 
proportional reduction) and those patients receiving oxygen without invasive mechanical ventilation (by age-adjusted 
percentage points 4.1, approximately one fifth of proportional reduction). 
However, they did not note any evidence of dexamethasone benefits in those patients that were not receiving any re-
spiratory support at randomization, and the findings were similar with the possible harm in this subgroup. In all those 
patients of COVID-19 having common inflammatory lung damage and they were treated for more than 07 days after 
onset of symptoms, the use of dexamethasone was also found to be effective. [4]
Recently, another trial was conducted in which the patients having acute respiratory distress syndrome and also re-
ceiving mechanical ventilation, the mortality at 60 days was 15% lower in the dexamethasone group as compared to the 
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Primary and Secondary Outcomes
Number/Total number of patients (%)
Initial outcome Usual Care(N=2104)
Dexamethasone
(N=2104)
 Risk Ratio or Rate
(95% CI)
Primary Outcome
Mortality at 28 days 1110/4321 (25.7) 482/2104 (22.9) 0.83 (0.75-0.93)
Secondary Outcomes
Discharged within 28 days from the hospital 2745/4321 (63.5) 1413/2104 (67.2) 1.10 (1.03–1.17)
Invasive mechanical ventilation 285/3638 (7.8) 102/1780 (5.7) 0.77 (0.62–0.95)
Death or invasive mechanical ventilation 994/3638 (27.3) 456/1780 (25.6) 0.92 (0.84–1.01)
Deaths 827/3638 (22.7) 387/1780 (21.7) 0.93 (0.84–1.03)
Table 1. Dexamethasone in COVID-19 Hospitalized Patients. [4]
other group receiving usual care. [5] These findings are also parallel to the results of  Group. [4]
These trials provide evidence that all COVID-19 patients that receiving respiratory support, when treated with a dose 
of 6 mg once daily at least for up to 10 days with dexamethasone reduces 28- day mortality. They did not found any ben-
efit and also the harm possibility among all those patients who did not need any kind of respiratory support. [4]
So, dexamethasone is now present on the essential medicines list of WHO and easily available throughout the world at 
minimum price. 
The National Institutes of Health (NIH) in the USA and the chief medical officers of U.K issued and updated guidelines 
to recommend the use of glucocorticoids in COVID-19 hospitalized patients. [4] 
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